Minding the gap: Unlockingthe therapeutic potentialof aptamers and making up for lost time
Annalisa Di Ruscio, Vittorio de Franciscis
Molecular Therapy: Nucleic Acids · 2022
doi:10.1016/j.omtn.2022.07.012 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Aptamers are RNAs that can bind proteins directly and modulate protein-protein interactions. Given their therapeutic potential, aptamers would be expected to capture the interest of both scientists and investors. However, concerns regarding safety, efficacy, and delivery have delayed aptamer development and dampened investor support. Herein, we discuss the major hurdles stalling the translational application of aptamers over recent years and focus on approaches to overcome current barriers and attract the scientific community and investors to the aptamer field.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.